Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Jörger M, Behringer D, Ko Y, Hilger R, Roessler M, Kloft C, Henrich A, Moritz B, Miller M, Salamone S, Kopp H, Mayer F, von Pawel J, Kraff S, Fischer J, Eberhardt W, Gauler T, Mueller L, Reinmuth N, Reck M, Kimmich M, Jaehde U. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2016; 27:1895-902.
Aug 8, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Aug 8, 2016
Ann Oncol 2016; 27:1895-902
Jörger Markus, Behringer D M, Ko Y-D, Hilger R A, Roessler M, Kloft C, Henrich A, Moritz B, Miller M C, Salamone S J, Kopp H-G, Mayer F, von Pawel J, Kraff S, Fischer J R, Eberhardt W, Gauler T C, Mueller L, Reinmuth N, Reck M, Kimmich M, Jaehde U
more
